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The aim of this study is to assess the practice of heparin administration in real-
life situations. This study was conducted at the coronary care unit (CCU) in
one of the busiest hospitals in Kuwait; with special attention to the rate of
heparin resistance, potential factor that may predict resistance or responsive-
ness and heparin related complications. A prospective observational study was
conducted in Farwania hospital over a 4-month period; this study included 146
patients admitted to the CCU. Patients were treated with UFH according to a
standard normogram. Several variables were collected and analyzed, includ-
ing demographic data, initial diagnosis, activated partial thromboplastin time
(APTT) on admission and at 6, 24, and 48h after UFH administration, and any
complications that occurred. A signiﬁcant number of patients had subthera-
peutic APTT at 6, 24, and 48h (41.1%, 42.3%, and 46.7%, respectively). There
were four factors that predicted heparin resistance, including race, gender, ad-
mitting diagnosis (unstable angina vs. acute myocardial infarction), and an
APTT ratio of less than one on admission. There was no signiﬁcant difference
in the rate of development of complications among different groups. Heparin
resistance is a common phenomenon especially in the ﬁrst period of heparin
therapy. Special attention should be given to some groups like females, pa-
tients admitted with unstable angina, and those with APTT below the normal
range. Evidence based protocols for Heparin administration and monitoring
must be adopted to prevent the risk of under or over anticoagulation.
Introduction
Unfractionated heparin (UFH) is an antithrombotic agent
used as a ﬁrst line therapy in the management and pro-
phylaxis of thromboembolic disorders and acute coro-
nary syndromes [1]. Heparin is an indirect thrombin
inhibitor, which complexes with antithrombin (AT, for-
merly known as AT III) and converts this circulating co-
factor from a slow-to-rapid inactivator of thrombin, factor
Xa, and to a lesser extent, factors XIIa, XIa, and IXa [2,3].
Heparin has a number of major limitations, includ-
ing a narrow therapeutic window of adequate antico-
agulation without running an increased risk of bleed-
ing and a highly variable dose–response relation that re-
quires monitoring by laboratory testing. Heparin resis-
tance is a known phenomenon, especially in the early
phase of heparin therapy, which is attributed to nonspe-
ciﬁc binding of UFH to the endothelial cells and plasma
proteins, active removal of UFH by the reticuloendothe-
lial cells, and neutralization by platelet factor-4 [4,5].
This initial phase of heparin resistance may put patients
at risk of progression of the underlying thrombotic pro-
cess [6]. Therefore, close monitoring of the activated par-
tial thromboplastin time (APTT) and heparin dose ad-
justment is recommended to reduce this risk. In Kuwait,
as well as in the Middle East, UFH is the most widely
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used anticoagulant in the management of thromboem-
bolic disorders and acute coronary syndromes. However,
the practice of anticoagulation, potential practice pitfalls,
and the possible factors that could inﬂuence the outcome
have never been previously explored in studies from the
Middle East.
Methods
The study was conducted in Farwania hospital, a large
community-based hospital in Kuwait serving a popula-
tion of 700,000. The data were collected prospectively
over a period of 4 months. The treating physician were
blinded to data collection. The Institutional Review Board
at Farwaniya Hospital approved the study. Informed con-
sent was obtained from each participant.
Inclusion Criteria
All patients admitted to the coronary care unit (CCU)
with a diagnosis of myocardial infarction or unstable
angina and requiring UFH were included in the study.
Patients who were found later to have noncardiac chest
pain but received UFH in the initial phase of admission to
the CCU were also included.
Exclusion Criteria
Patients who did not receive UFH during their stay in the
CCU were excluded from the study.
Primary Outcome
The primary outcome was to assess the number of pa-
tients who achieved therapeutic APTT with UFH therapy
within the ﬁrst 6, 24. and 48h of their admission.
Secondary Outcome
Assessment of any factors that may inﬂuence the achieve-
ment of a therapeutic range determined by APTT in the
initial phase of the treatment, and examination of any
potential complications that may result from under- or
overanticoagulation with UFH such as recurrence of is-
chemia, progression of thrombus, pulmonary embolism
(PE), stroke, death, and bleeding.
Treatment
The dose of heparin was adjusted by treating physician
according to a heparin normogram in which 5000 unit
heparin bolus is given initially, followed by an intra-
venous infusion of heparin at a rate of 1000 units/h. Fur-
ther readjustment of the dose depends on the APTT test
result. APTT was measured every 6 h, and the dose of
heparin was adjusted to keep APTT in the therapeutic
range.
Laboratory Monitoring
The anticoagulant effect of UFH is assessed by APTT. An
APTT ratio of 1.5–2.5 times the mean was considered
therapeutic in the local hospital laboratory. A subthera-
peutic APTT was deﬁned as an APTT ratio that is less than
1.5. Any ratio higher than 2.5 is considered overantico-
agulated state.
APTT was recorded on admission and then at 6, 24, 48,
and 72h of starting UFH. Those patients who required a
longer period of anticoagulation had their APTT recorded
in the subsequent days, and the daily total dose of UFH is
recorded.
Statistical Analysis
Analysis of data is mainly descriptive using means and
standard deviations or median and ranges. The Pearson
Chi-square test was used to assess secondary out-
comes.
Results
At the end of the study period, 146 patients were in-
cluded. Patient’s characteristics and diagnosis on admis-
sion are summarized in table 1.
The mean duration of UFH therapy was 3.64 days,
ranging from 1 to 15 days.
Primary Endpoints
Out of 146 patients, the number of patients who achieved
the therapeutic APTT range after 6 h of UFH therapy was
39 (26.7%), whereas 60 (41.1%) patients where subther-
apeutic, and 47 (32.2%) patients were over anticoagu-
lated. At 24 h of admission, 137 patients were receiving
heparin. Forty-one patients (30%) were in the thera-
peutic range, whereas 58 (42.3%) were subtherapeutic
and 38 (27.7%) were overanticoagulated. At 48 h, 35
(33.3%) patients out of 105 who were still on heparin
had a therapeutic APTT, while 49 (46.7%) patients were
in the subtherapeutic range, and 20 (20%) were overan-
ticoagulated (Table 2).
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Table 1 Baseline characteristics
Number (%) Total
Sex
Male 99 (67.8)
Female 47 (32.2) 146(100%)
Age:
Range 23–92 years
Mean 52.51 years
Racial background
Kuwaiti Arabs 64 (43.8)
Non-Kuwaiti Arabs 44 (30.1)
Asians 35 (24)
Orientals 1 (0.7)
Caucasian 2 (1.4)
Diagnosis
DVT 2 (1.4)
PE 2 (1.4)
Unstable angina 80 (54.8)
MI 43 (29.5)
Stroke 4 (2.7)
Systemic embolism 2 (1.4)
Atrial ﬁbrillation 9 (6.2)
CHF 4 (2.7)
Table 2 APTT at 6, 24, and 48 h
APTT (Ratio) 6 h 24 h 48 h
Sub-therapeutic 60 (41.1%) 58 (42.3%) 49 (46.7%)
Therapeutic 39 (26.7%) 41 (30%) 35 (33.3%)
Over anticoagulation 47 (32.2%) 38 (27.7%) 21 (20%)
Total number 146 137 105
Secondary Endpoints
Arabs are more likely to be subtherapeutic than non-
Arabs at 6h of starting heparin therapy (48% vs. 21%.
P = 0.006). However, this difference disappeared at 24
and 48h (42% vs. 41% and 48% vs. 42%, respectively).
The percentage of females who remained in the sub-
therapeutic APTT range after 6h of heparin therapy was
55.3% compared with 34.7% in males (P = 0.003). This
trend continued after 24h (54.4% vs. 38.3%) and 48h
(53.1% vs. 44.4%).
Patients with unstable angina show more resistance to
UFH than those with acute myocardial infarction in the
ﬁrst 48h of UFH therapy. At 6h of heparin therapy, 45%
of patients with unstable angina were still in the subther-
apeutic range compared with 20.9% of patients admitted
with acute myocardial infarction (P = 0.004). This trend
persisted at 24 and 48 h (51.3% vs. 31.6% and 53.7% vs.
34.5%, respectively).
Out of 146 patients, 88 (60.3%) had an APTT ratio be-
low one at the time of admission, whereas 58 patients
Table 3 Association between baseline APTT ratio and heparin resistance
at 6 h
APTT ratio on admission APTT at 6 h APTT < 1 APTT = 1T o t a l
Subtherapeutic 45 15 60
Therapeutic 19 20 39
Over-anticoagulation 24 23 47
Total number 88 58 146
Table 4 Complications rate
Bleeding 8 (5.5%)
Stroke 2 (1.4%)
PE 3 (2.1%)
Extension of the thrombus 1 (0.7%)
Death 1 (0.7%)
had an APTT ratio of one or more. Forty-ﬁve patients
(51.1%) from the ﬁrst group (with low APTT ratio) were
subtherapeutic in the ﬁrst 6h after starting heparin ther-
apy. On the other hand, out of 60 patients who were in
the subtherapeutic range at 6 h of heparin therapy, 45
(75%) had an APTT ratio less than one on admission, as
opposed to the 15 (25%) patients with an APTT ratio of
one or more (P = 0.010). (Table 3)
Bleeding attributed to UFH occurred in 8 (5.5%) pa-
tients. The bleeding episodes were epistaxis (2cases),
hemoptysis (2cases), hematuria (1case), localized cuta-
neous hematoma (1case), bleeding from intravenous site
(1case), and gum bleeding (1 case). Most of the bleeding
episodes were mild and did not lead to discontinuation of
heparin, except in one patient with clinically signiﬁcant
hemoptysis (Table 4).
The rate of development of recurrence of ischemia,
progression of thrombus, pulmonary embolism, ischemic
stroke, or death is shown in table 4.
Follow-up platelet count was not routinely ordered by
treating physicians to monitor Heparin induced thrombo-
cytopenia; it was ordered in one patient who had a com-
plete blood count after a bleeding episode.
Discussion
UFH is a commonly used anticoagulant in CCUs world-
wide, appearing in several guidelines for the manage-
ment of acute coronary syndromes and related disorders
as a grade 1A recommendation[1, 7–9, 10]. The clinical
effectiveness of heparin is dependent on achieving an
in vitro deﬁned anticoagulant effect, although there is
considerable in vivo variation in response to a ﬁxed dose
of heparin between individuals. This is partly reﬂective
of the pharmacokinetic limitations of heparin caused by
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the binding of heparin to plasma proteins, in addition to
the problems encountered in measuring its desired anti-
coagulant effect. For these reasons, we sometimes have
patients with the phenomenon known as ‘heparin resis-
tance’. This should be taken into consideration to prevent
the overadministration of heparin, with potential hemor-
rhagic consequences, particularly postoperatively, in car-
diac bypass surgery or in acute coronary syndromes as
shown in this study. In the treatment of venous throm-
boembolism, this phenomenon is of unclear clinical sig-
niﬁcance.
In the context of venous thromboembolism, heparin
resistance is deﬁned as the need for more than 35,000
units in a 24h period to prolong the APTT to reach ther-
apeutic range. In contrast, during cardiac bypass proce-
dures the deﬁnition of heparin resistance is based on the
activated clotting time (ACT), with at least one ACT less
than 400 seconds after heparinization and/or the need for
exogenous AT administration.
In the current study, a high rate of inadequate hep-
arinization in patients who were in need of full antico-
agulation in the initial phase of their illness was seen in
41.1% of the patients after 6h of heparin therapy. This
phenomenon had remained after 24 and 48 h of hep-
arin therapy, putting the patients at risk of extension of
their thrombotic disorder [11–14]. The potential reasons
behind the high rate of inadequate heparinization in the
initial phase of heparin therapy can be attributed to the
unawareness of the medical personnel of heparin phar-
macokinetics, leading to inappropriate initial dosing and
dose adjustments. Some physicians are also overcautious
while using anticoagulants because of the potential bleed-
ing risk.
An audit of physicians’ practices at three university-
afﬁliated hospitals documented that 60% of treated pa-
tients failed to achieve an adequate APTT response (ra-
tio of 1.5) during the initial 24h of therapy, and that
30–40% of patients remained subtherapeutic over the
next 3–4 days [3]. These problems have been allevi-
ated with the use of protocols for the administration of
heparin.
Data analysis has revealed four variables that may pre-
dict higher heparin resistance rate. The ﬁrst factor is race.
Arabs are more resistant to heparin therapy especially in
the early phase of treatment compared with non-Arabs.
This difference disappeared in subsequent days of heparin
therapy. This observation needs conﬁrmation in future
studies since there has never been any similar observa-
tions in relation to heparin resistance between races in
previous reports.
The second factor is gender. Females are more resis-
tant to heparin than males in our study. The higher rate
of resistance to heparin in females extended up to 48h
(Table 2). A possible explanation may be the higher level
of factor VIII in females because of estrogen [8,9].
The third factor is the type of the coronary artery prob-
lem on admission. Patients who were admitted with un-
stable angina showed more resistance to heparin than
those with acute myocardial infarction. Again, this ob-
servation has not been reported in previous reports and
might be unique to the population in this study. It is pos-
sible that some physicians treated the patients with acute
myocardial infarction more aggressively than they treated
those with unstable angina. Another explanation is the
effect of thrombolytic therapy on the coagulation system,
leading to the depletion of several coagulation factors and
thus resulting in less resistance to heparin therapy.
Finally, those Patients with an APTT ratio below one
at presentation showed resistance to heparin therapy and
were more likely to be subtherapeutic at 6 and 24h of
their admission; however, this difference disappears in
the subsequent hours.
The Bleeding rate in this study was 5.5%, similar to
rates in published literature. Most of bleeding episodes
were minor. The rate of development of PE, progression
of thrombus, ischemic stroke, and recurrence of angina
were not signiﬁcantly different among groups. A Lack of
follow-up of platelet counts to monitor for HIT syndrome
may reﬂect an unawareness of this phenomenon, which
is associated with heparin therapy [15].
The use of evidence based Heparin protocols will help
in preventing large ﬂuctuations in APTT results and re-
duce the possibility of occurrence of heparin resistance in
the initial phase of heparin therapy [16–19].
There is still much to learn about heparin resistance. In
the context of venous thromboembolism, is heparin resis-
tance of any clinical relevance? What is the outcome in
patients treated with empirical doses of heparin when the
APTT had not reached therapeutic range? In the context
of cardiac bypass surgery or critical care units where acti-
vation of coagulation and ﬁbrinolysis involve yet poorly
understood mechanisms, and where postoperative bleed-
ing complications lead to increased blood product us-
age and other postoperative complications, what is the
optimal means of monitoring the anticoagulant and an-
tithrombotic effect? With the recent development of new
synthetic indirect and direct factor Xa inhibitors, these
questions become increasingly pressing.
Low molecular weight heparin (LMWH) would be rea-
sonable substitution for UFH because of their predicted
effect and better bioavailability, as well as easy admin-
istration. LMWHs do not need laboratory monitoring,
making them the drug of choice in the management
of thromboembolic disorders and acute coronary syn-
dromes [20]. Additionally, LMWHs have less plasma pro-
tein binding and are less affected by PF4.
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Conclusion
Anticoagulation with UFH in CCUs has several pitfalls
that are mainly related to its properties and physicians’
unawareness of its pharmacokinetics and pharmacody-
namics. Adopting an approved heparin normogram and
frequent monitoring of APTT, with adjustment of the
dose accordingly, will result in minimization of these dif-
ﬁculties. Recognizing populations at risk of heparin resis-
tance is of extreme importance and requires several stud-
ies worldwide to conﬁrm the observed variables that may
lead to heparin resistance.
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